Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Cancer Immunol Immunother. 2015 Sep 21;64(12):1531–1539. doi: 10.1007/s00262-015-1758-5

Fig. 2.

Fig. 2

Cumulative incidence of immune response, or the measure of immune response over time, over first 8 weeks of the trial period. a Includes all study participants by age grouping participants into either younger or older than 64 years b. Uses only participants within the high responder arms (Mel 43 without GM-CSF and Mel 44 with 6MHP) stratifying by age c. All study participants by gender d. Includes only female patients and further stratifies them into younger or older than 50 years of age to approximate for menopause